Pathology and bio markers of prostate cancer.

abstract：INTRODUCTION:Multidisciplinary team (MDT) meetings use precise prognostic factors to select treatment options for patients with prostate cancer. Comorbidity is judged subjectively. Recent publications favour the Charlson comorbidity score (CS) for the use in the management of prostate cancer. We assess the feasibility ...

journal_title：Prostate cancer and prostatic diseases

authors： Kastner C,Armitage J,Kimble A,Rawal J,Carter PG,Venn S

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Focal therapy is an emerging mini-invasive treatment modality for localized prostate cancer aimed to reduce the morbidity associated with radical therapy while maintaining optimal cancer control. We report the mid-term oncological and functional results of primary hemiablation high-intensity focused ultrasou...

journal_title：Prostate cancer and prostatic diseases

authors： van Velthoven R,Aoun F,Marcelis Q,Albisinni S,Zanaty M,Lemort M,Peltier A,Limani K

更新日期：2016-03-01 00:00:00

abstract：BACKGROUND:While direct-to-consumer (DTC) medical advertising can provide useful information, it also risks oversimplification and being misleading. For an abbreviated prostate cancer treatment regimen called "ultrahypofractionation" (UHF), advertising has been used for CyberKnife (CK), a common delivery system for ste...

journal_title：Prostate cancer and prostatic diseases

authors： Caputo JM,Lee HJ,Chiles B,Hyams ES

更新日期：2020-12-01 00:00:00

abstract：:This literature review discusses the theoretical background of 5alpha-reductase inhibitor (5ARI) treatment and the resulting clinical implications. A Medline-based search for peer-reviewed articles addressing 5ARIs, benign prostatic hyperplasia and prostate cancer was performed. The 5ARIs Finasteride and Dutasteride, ...

journal_title：Prostate cancer and prostatic diseases

authors： Dörsam J,Altwein J

更新日期：2009-01-01 00:00:00

abstract：:Testosterone depletion is the keystone for therapy of patients metastic prostatic carcinoma. Our objective was to investigate Leydig cell function and testosterone levels after withdrawal of long-term endocrine treatment in patients with prostatic carcinoma. Thirteen patients with prostatic carcinoma, previously treat...

journal_title：Prostate cancer and prostatic diseases

authors： Tomic R,Ljungberg B

更新日期：1999-07-01 00:00:00

abstract：:New approaches to treat prostate cancer (PCA) are utilizing gene therapy and aim to correct the disease at the genetic level. Getting a gene efficiently into the target cell is the subject of much interest. We used a holmium laser for transfecting rat PCA cells with the reporter gene pEGFP. By FACS analysis and fluore...

journal_title：Prostate cancer and prostatic diseases

authors： Sagi S,Knoll T,Trojan L,Schaaf A,Alken P,Michel MS

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Epidemiologic evidence for a serum cholesterol-prostate cancer link is mixed. Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions...

journal_title：Prostate cancer and prostatic diseases

authors： Jamnagerwalla J,Howard LE,Allott EH,Vidal AC,Moreira DM,Castro-Santamaria R,Andriole GL,Freeman MR,Freedland SJ

更新日期：2018-06-01 00:00:00

abstract：:Side effects accompanying androgen deprivation therapy (ADT), including sarcopenia, loss of bone mass and reduction in muscle strength, can compromise physical function, particularly in older patients. Exercise, specifically resistance training, may be an effective and cost-efficient strategy to limit or even reverse ...

journal_title：Prostate cancer and prostatic diseases

authors： Galvão DA,Taaffe DR,Spry N,Newton RU

更新日期：2007-01-01 00:00:00

abstract：:The purpose of the present study was to perform a BPH risk factor analysis in men, relating the prostate gland volume to components of the metabolic syndrome and to identify clues to the etiology of BPH. Our material comprised a consecutive series of 158 patients with lower urinary tract symptoms with or without manif...

journal_title：Prostate cancer and prostatic diseases

authors： Hammarsten J,Högstedt B,Holthuis N,Mellström D

更新日期：1998-03-01 00:00:00

abstract：:To determine whether needle size influences a patient's perception of pain, 50 patients requiring hormonal manipulation for prostate cancer were blindfolded and randomised to receive two goserelin ('Zoladex') or two leuprorelin ('Prostap') injections, using 16- or 23-gauge needles, respectively. Median visual analogue...

journal_title：Prostate cancer and prostatic diseases

authors： Montgomery BS,Borwell JP,Higgins DM

更新日期：2005-01-01 00:00:00

abstract：:The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and p...

journal_title：Prostate cancer and prostatic diseases

authors： Armstrong AJ,Halabi S,de Wit R,Tannock IF,Eisenberger M

更新日期：2009-01-01 00:00:00

abstract：:This corrects the article DOI: 10.1038/pcan.2017.5. ...

journal_title：Prostate cancer and prostatic diseases

authors： Weiner AB,Matulewicz RS,Schaeffer EM,Liauw SL,Feinglass JM,Eggener SE

更新日期：2017-12-01 00:00:00

abstract：BACKGROUND:Understanding the mechanisms driving disease progression is fundamental to identifying new therapeutic targets for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). Owing to the prevalence of bone metastases in mCRPC, obtaining sufficient tumor tissue for analysis has histori...

journal_title：Prostate cancer and prostatic diseases

authors： McKay RR,Zukotynski KA,Werner L,Voznesensky O,Wu JS,Smith SE,Jiang Z,Melnick K,Yuan X,Kantoff PW,Montgomery B,Balk SP,Taplin ME

更新日期：2014-12-01 00:00:00

abstract：OBJECTIVES:Neuroendocrine prostate cancers (NEPCs) are rare. The current lack of consensus for clinical, biological and pathological characterization as well as therapeutic approach makes the management of those tumors a clinical challenge. This literature review aims to summarize available data on the characterization...

journal_title：Prostate cancer and prostatic diseases

authors： Sargos P,Ferretti L,Gross-Goupil M,Orre M,Cornelis F,Henriques de Figueiredo B,Houédé N,Merino C,Roubaud G,Dallaudiére B,Richaud P,Fléchon A

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:The Gleason grading system in prostatectomy specimens following receipt of neoadjuvant therapy has been considered inaccurate. However, with continuing expansion of novel therapeutics, it is important to understand whether the Gleason system can be effectively utilized in this setting. The aim of this study ...

journal_title：Prostate cancer and prostatic diseases

authors： Stewart SB,Cheville JC,Sebo TJ,Frank I,Boorjian SA,Thompson RH,Gettman MT,Tollefson MK,Umbriet EC,Psutka SP,Bergstralh EJ,Rangel L,Karnes RJ

更新日期：2014-12-01 00:00:00

abstract：:We conducted a study in order to characterize changes after withdrawal of androgen ablation (AA) for prostate cancer. AA was withdrawn in 38 Japanese patients with prostate cancer who had undergone this therapy for various periods. Patients were stratified into those who had undergone AA for less than 24 months (Group...

journal_title：Prostate cancer and prostatic diseases

authors： Egawa S,Okusa H,Matsumoto K,Suyama K,Baba S

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Patients with prostate cancer are at risk of impaired bone health. Prostate cancer has a propensity to metastasize to bone, after which patients are at risk of skeletal-related events (SREs). These complications are associated with increased mortality, substantial pain, and reduced quality of life. Patients ...

journal_title：Prostate cancer and prostatic diseases

authors： Miller K,Steger GG,Niepel D,Lüftner D

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:Gonadotrophin releasing hormone (GnRH) agonists and antagonists reduce testosterone levels for the treatment of advanced and metastatic prostate cancer. Androgen deprivation therapy (ADT) is associated with increased risk of cardiovascular (CV) events and CV disease (CVD), especially in patients with preexis...

journal_title：Prostate cancer and prostatic diseases

authors： Margel D,Ber Y,Peer A,Shavit-Grievink L,Pinthus JH,Witberg G,Baniel J,Kedar D,Rosenbaum E

更新日期：2020-07-31 00:00:00

abstract：BACKGROUND:The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is controversial. To examine the risk of 10-year cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathological characteristics of very high-risk cT3b/4 PCa patient...

journal_title：Prostate cancer and prostatic diseases

authors： Moltzahn F,Karnes J,Gontero P,Kneitz B,Tombal B,Bader P,Briganti A,Montorsi F,Van Poppel H,Joniau S,Spahn M

更新日期：2015-03-01 00:00:00

abstract：BACKGROUND:Patients with high-risk prostate cancer have an increased likelihood of experiencing a relapse following radical prostatectomy (RP). We previously conducted three neoadjuvant androgen-deprivation therapy (ADT) trials prior to RP in unfavorable intermediate and high-risk disease. METHODS:In this analysis, we...

journal_title：Prostate cancer and prostatic diseases

authors： McKay RR,Montgomery B,Xie W,Zhang Z,Bubley GJ,Lin DW,Preston MA,Trinh QD,Chang P,Wagner AA,Mostaghel EA,Kantoff PW,Nelson PS,Kibel AS,Taplin ME

更新日期：2018-09-01 00:00:00

abstract：:We have identified a novel function for a member of the transient receptor potential (TRP) protein super-family, TRPM2, in prostate cancer cell proliferation. TRPM2 encodes a non-selective cation-permeable ion channel. We found that selectively knocking down TRPM2 with the small interfering RNA technique inhibited the...

journal_title：Prostate cancer and prostatic diseases

authors： Zeng X,Sikka SC,Huang L,Sun C,Xu C,Jia D,Abdel-Mageed AB,Pottle JE,Taylor JT,Li M

更新日期：2010-06-01 00:00:00

abstract：:The TGFBR1*6A (*6A) variant in exon 1 of the TGFBR1 gene has been postulated as a putative tumor susceptibility allele in several studies. We have performed a case-control study in 537 men with histologically verified prostate cancer and in 488 unrelated controls to investigate the association of *6A with prostate can...

journal_title：Prostate cancer and prostatic diseases

authors： Suarez BK,Pal P,Jin CH,Kaushal R,Sun G,Jin L,Pasche B,Deka R,Catalona WJ

更新日期：2005-01-01 00:00:00

abstract：OBJECTIVE:To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs)-based prognosis. PATIENTS AND METHODS:A two-cohort-based evaluation for serum CGA for prognostication in C...

journal_title：Prostate cancer and prostatic diseases

authors： Giridhar KV,Sanhueza C,Hillman DW,Alkhateeb H,Carlson R,Tan W,Costello BA,Quevedo F,Pagliaro L,Kohli M

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond typical men with very low- or low-risk disease. We sought to review the current experience with AS for men with int...

journal_title：Prostate cancer and prostatic diseases

authors： Dall'Era MA,Klotz L

更新日期：2017-03-01 00:00:00

abstract：BACKGROUND:Several randomized control trials (RCTs) have showed that adding either abiraterone acetate (AA) or docetaxel (D) to androgen-deprivation therapy (ADT) improves survival of metastatic castration-sensitive prostate cancer patients (mCSPC). Yet, the cost-effectiveness of these treatment options has not been fu...

journal_title：Prostate cancer and prostatic diseases

authors： Chiang CL,So TH,Lam TC,Choi HCW

更新日期：2020-03-01 00:00:00

abstract：:Radiofrequency interstitial tumor ablation (RITA) is a thermal ablation method that uses needles and low radiofrequency (RF) energy. The aim of our study was to evaluate the histopathology of thermal lesions induced by RF energy delivered interstitially in prostate cancer patients who subsequently underwent prostatect...

journal_title：Prostate cancer and prostatic diseases

authors： Patriarca C,Bergamaschi F,Gazzano G,Corrada P,Ordesi G,Zanitzer L,Di Pasquale M,Giunta P,Campo B

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Large multicenter studies comparing outcomes between TURP and photoselective vaporization of the prostate (PVP) are sparse, with no studies having compared the influence of trainee involvement on these outcomes. Our objectives were to assess 30-day outcomes after TURP and PVP with respect to trainee involvem...

journal_title：Prostate cancer and prostatic diseases

authors： Olcese SP,Derosa R,Kern SQ,Lustik MB,Sterbis JR,McMann LP

更新日期：2014-09-01 00:00:00

abstract：INTRODUCTION:Approximately 85% of patients who die from prostate cancer present the spread of bone metastases. Even though the radiological appearance of such metastases is osteoblastic, it is now known that these lesions coexist in their microenvironment with blastic and lytic lesions. The process always begins with b...

journal_title：Prostate cancer and prostatic diseases

authors： Rodrigues P,Hering F,Campagnari JC

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant hormonal therapy (NHT) before radical prostatectomy (RP). The majority of them included mainly low and intermediate risk prostate cancer (PCa) without specifically assessing PCa-related death (PCRD). Thus, there i...

journal_title：Prostate cancer and prostatic diseases

authors： Tosco L,Laenen A,Briganti A,Gontero P,Karnes RJ,Albersen M,Bastian PJ,Chlosta P,Claessens F,Chun FK,Everaerts W,Gratzke C,Graefen M,Kneitz B,Marchioro G,Salas RS,Tombal B,Van den Broeck T,Moris L,Battaglia A,van d

更新日期：2017-12-01 00:00:00

abstract：BACKGROUND:Unlike in other mouse models of atherogenesis, it has recently been suggested that orchiectomy plays a role in accelerating atherosclerosis and inhibiting the progression of cardiovascular disease in the ApoE-/-:Ins2+/Akita mouse model of hyperglycemia. Androgen-deprivation therapy (ADT) is a common treatmen...

journal_title：Prostate cancer and prostatic diseases

authors： Duivenvoorden WCM,Naeim M,Hopmans SN,Yousef S,Werstuck GH,Dason S,Pinthus JH

更新日期：2020-09-28 00:00:00